DARA BioSciences, Inc. Announces it is Indefinitely Suspending Its Public Unit Offering
July 01, 2010 14:23 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., July 1, 2010 (GLOBE NEWSWIRE) -- On May 17, 2010, DARA BioSciences, Inc. (Nasdaq:DARA) issued a press release announcing that it had commenced an underwritten public offering of $10...
DARA BioSciences Reports on SurgiVision Receiving FDA Clearance to Market Its ClearPoint System
June 28, 2010 16:30 ET
|
DARA BioSciences, Inc.
DARA was an Early Investor in SurgiVision and Presently Owns 1.6 Million Shares and Warrants to Purchase an Additional 405,000 Shares
RALEIGH, N.C., June 28, 2010 (GLOBE NEWSWIRE) -- DARA...
DARA BioSciences to Present at Sidoti & Company 2010 Semiannual Micro-Cap Conference and OneMedForum 2010 New York Conference
June 07, 2010 09:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., June 7, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARAD) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at...
DARA Regains NASDAQ Minimum Bid Price Compliance
June 01, 2010 10:15 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., June 1, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARAD) today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum...
DARA BioSciences to Raise Up to $10,000,000 Through Public Offering
May 17, 2010 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 17, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (the "Company") (Nasdaq:DARAD) announced today that it has commenced an underwritten public offering of $10 million of units...
DARA BioSciences, Inc. Announces Results of Annual Meeting and Implementation of a 16-for-1 Reverse Stock Split
May 12, 2010 17:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 12, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (the "Company") (Nasdaq:DARA) announced today that at the 2010 Annual Meeting of Stockholders, the Company's stockholders...
DARA BioSciences Enters Into a Clinical Trial Collaboration With the Division of Cancer Prevention (DCP), National Cancer Institute (NCI) for the Clinical Development of KRN5500
April 27, 2010 10:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 27, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of...
DARA BioSciences to Present Results of a Phase 2 Clinical Study for KRN5500 at the "Third International Congress on Neuropathic Pain"
April 20, 2010 10:15 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 20, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the company has been selected by the Scientific Programme Committee to present results from...
DARA BioSciences Initiates a Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
March 25, 2010 10:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 25, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated...
DARA Receives Anticipated Notice of Non-Compliance From NASDAQ
March 19, 2010 17:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 19, 2010 (GLOBE NEWSWIRE) -- On March 16, 2010, DARA BioSciences, Inc. (Nasdaq:DARA) received notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC...